Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a company with promising potential, as its physics-based approach to developing nanotherapeutics has the potential to revolutionize cancer treatment. However, the company faces risks, including potential clinical trial failures and regulatory setbacks, as well as potential financial risks due to its high debt and potential need for dilutive financing. The company also faces competition in the market and uncertainties around commercial performance of its products. However, with near-term milestones and potential collaborations, Nanobiotix is positioned for growth and success in the future.

Bears say

Nanobiotix is facing potential risks and a negative outlook due to potential clinical trial failures, safety concerns, and regulatory setbacks for its pipeline candidates. Additionally, commercial performance for its lead program may not meet expectations as it is highly novel, which could result in lower revenues and profitability. Furthermore, the company carries a high level of financial risk as it relies heavily on milestone payments and royalties rather than consistent, solid revenues from approved products.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.